

The effect of test compounds JW 1-3 in the transplant model of psoriasis.

Published: 13-03-2018

Last updated: 12-04-2024

The aim of the project is to study the effect of JW 1-3 test compounds on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical research.

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Epidermal and dermal conditions
Study type	Observational invasive

Summary

ID

NL-OMON46431

Source

ToetsingOnline

Brief title

Transplant model of psoriasis.

Condition

- Epidermal and dermal conditions

Synonym

Psoriasis

Research involving

Human

Sponsors and support

Primary sponsor: Derphartox

Source(s) of monetary or material Support: Farmaceutische industrie

Intervention

Keyword: model, psoriasis, transplant

Outcome measures

Primary outcome

Effect on typical psoriasis skin features after treatment with JW 1-3 test compounds.

Secondary outcome

-

Study description

Background summary

Psoriasis is an autoimmune disease in which proinflammatory protein mediators, released by skin cells and infiltrating cells, cause an abnormal cell division and differentiation. It may be possible to treat psoriasis using drugs aimed at preventing the synthesis of such mediators.

Study objective

The aim of the project is to study the effect of JW 1-3 test compounds on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical research.

Study design

Non-lesional skin biopsies of 6 mm in diameter will be treated with JW 1-3 test compounds using the transplant model of psoriasis. By measuring the effect on typical psoriasis skin features, it is possible to establish the most effective compound, the right formulation and dose for further clinical research.

Study burden and risks

The health risks associated with taking blood & skin biopsies are small. It is possible to obtain a slight scar formation and/or discolouration at the site of the biopsy punch.

Contacts

Public

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Scientific

Derphartox

Wytemaweg 80
Rotterdam 3015 CN
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

Patients with moderate to severe psoriasis

Exclusion criteria

Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate
Volunteers using local topical corticosteroids

Volunteers developing psoriasis at wound sites (Köbner phenomenon)

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 06-04-2018

Enrollment: 20

Type: Actual

Ethics review

Approved WMO

Date: 13-03-2018

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register

CCMO

ID

NL65119.098.18